PDS Biotechnology Corp — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PDS Biotechnology completed an initial closing of a PIPE financing led by Nant Capital (Dr. Patrick Soon-Shiong's firm), raising $11.3M gross proceeds through sale of 16.5M common shares, 23.5M pre-funded warrants, and 20M common warrants at prices of $0.2825 and $0.28217 per unit. A contingent milestone closing of up to $11M additional ($10M from Nant, $1M from AB Group Ltd.) will trigger upon FDA submission of a Phase 3 protocol for PDS0301. Dr. Soon-Shiong and James Banaag joined the board; NantWorks also received a one-year exclusive negotiation right for PDS0101 (HPV immunotherapy).
Why this rating
Capital infusion of $11.3M represents ~19% of $60.1M market cap; high-profile investor backing with potential $11M more on clinical milestone; funds advance lead asset (PDS0301) to Phase 3 and reduce debt burden.
Price action (we called it positive)
before filing · preread $0.38 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.